Haemonetics Corp. plans to buy back more than $40 million worth of its own stock in a move to boost its share price.
Who could blame them? Strong year-end earnings and sales failed to impress Wall Street, where the Braintree blood management company’s stock dropped more than 10 percent today in early-morning trading following the earnings announcement. Shares were down more than $5 before a slight lunchtime rebound.